<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491969</url>
  </required_header>
  <id_info>
    <org_study_id>LAoIHF</org_study_id>
    <nct_id>NCT03491969</nct_id>
  </id_info>
  <brief_title>Clinical Study of Lipoic Acid on Ischemic Heart Failure</brief_title>
  <official_title>Clinical Study of Lipoic Acid on Ischemic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy of alpha-lipoic acid(α-LA) on mortality in patients with&#xD;
      ischemic heart failure (NYHA Class II - IV and EF =&lt; 45%).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that had first occurrence of the composite endpoint</measure>
    <time_frame>up to 24 months</time_frame>
    <description>either cardiovascular (CV) death or heart failure (HF) hospitalization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Alpha-Lipoic Acid(α-LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha-Lipoic Acid(α-LA)</intervention_name>
    <description>200 mg, po, tid</description>
    <arm_group_label>Alpha-Lipoic Acid(α-LA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>200 mg, po, tid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients ≥ 18 years of age, male or female.&#xD;
&#xD;
               -  Patients with a diagnosis of AMI (&gt;30 days) according to the global definition.&#xD;
                  ③Patients with a diagnosis of CHF (NYHA class II-IV) and reduced ejection&#xD;
                  fraction (EF =&lt; 45%) and elevated BNP（NT-proBNP≥600pg/ml or BNP≥150pg/ml;&#xD;
                  NT-proBNP ≥400 pg/mL or BNP ≥100 pg/mL if patients was hospitalized for heart&#xD;
                  failure within 12months).&#xD;
&#xD;
                    -  Patients must be treated with standardized heart failure medications&#xD;
                       treatment at a stable dose for at least 4 weeks.&#xD;
&#xD;
                         -  Patients must give written informed consent before any assessment is&#xD;
                            performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5&#xD;
             half-lives of enrollment, whichever is longer.&#xD;
&#xD;
               -  allergy to any of the study drugs, drugs of similar chemical classes（Vitamin B）&#xD;
                  as well as known or suspected contraindications to the study drugs.&#xD;
&#xD;
                    -  Previous history of intolerance to recommended target doses of α-LA.&#xD;
&#xD;
                         -  Current acute decompensated HF (exacerbation of chronic HF manifested&#xD;
                            by signs and symptoms that may require intravenous therapy).&#xD;
&#xD;
                            ⑤ Symptomatic hypotension and/or a SBP &lt; 100 mmHg.&#xD;
&#xD;
                            ⑥ Severe liver function abnormalities (ALT or AST more than 3 times of&#xD;
                            the normal upper limit).&#xD;
&#xD;
                            ⑦ Estimated GFR &lt; 30 mL/min/1.73m2 as measured by the simplified MDRD&#xD;
                            formula.&#xD;
&#xD;
                            ⑧ Serum potassium &gt; 5.2 mmol/L.&#xD;
&#xD;
                            ⑨ Pregnant women or women preparing for birth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Xu Lei</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

